OUR PRODUCTS
Our Products Our drug discovery and development programs have resulted in innovative approaches by which physicians may use targeted molecular agents to more precisely treat cancer. With the limited efficacy and debilitating toxic effects of conventional cancer treatments, Introgen's low-toxicity approach to cancer treatment has drawn global interest from oncologists. Click on the links below to find out more information about each product candidate. Advexin® - p53 tumor suppressor therapy INGN 241 - mda-7 INGN 225 - p53 immunotherapy INGN 401 - nanoparticle formulation FUS-1 INGN 234 - p53 topical INGN 402 - nanoparticle formulation p53 INGN 403 - nanoparticle formulation mda-7 INGN 007 - oncolytic viral therapy						ADVEXIN INGN 241 INGN 225 INGN 401 INGN 234 INGN 402 INGN 403 INGN 007

	About Introgen   |  Contract Services   |  Investor Relations   |  PR / News   |  Our Products   |  Technologies	Powered by Dot Command Center, Inc.
© Copyright 2008. Introgen Therapeutics, Inc. All rights reserved.   |   Terms of Use   |   Privacy Policy		Site Map | Contact Us